Sleep Apnea News and Research

RSS

Researchers examine brain's role in breathing

Much of our knowledge of the brain's role in regulating breathing comes from research with mice and rats. A chemical receptor within the brain stem communicates with the central nervous system to generate the basic pattern of breathing. The next step is applying that information to human tissue to identify these critical components in the human brain and their medical implications.

21 Jan 2011

CareCore National and D3 partner to accelerate implementation of cancer care pathways

To improve quality and contain rising costs in cancer care, CareCore National and D3, an affiliate of UPMC, have formed a new company to accelerate implementation of cancer care pathways.

19 Jan 2011

Polysomnography may predict adverse outcomes following pediatric adenotonsillectomy: Study

Performing polysomnography prior to pediatric adenotonsillectomy may help identify children at a higher risk of developing postoperative respiratory complications, according to a report in the January issue of Archives of Otolaryngology - Head Neck Surgery, one of the JAMA/Archives journals.

18 Jan 2011

Metabolic cost of missing one night of sleep equivalent to walking two miles

In the first-ever quantification of energy expended by humans during sleep, a University of Colorado team has found that the metabolic cost of an adult missing one night of sleep is the equivalent of walking slightly less than two miles.

5 Jan 2011

New guideline provides evidence-based recommendation for children undergoing tonsillectomy

A multidisciplinary clinical practice guideline, "Tonsillectomy in Children" will be published in the January issue of Otolaryngology-Head and Neck Surgery.

3 Jan 2011

FDA approves Endo's FORTESTA Gel for low testosterone

Endo Pharmaceuticals today announced that the U.S. Food and Drug Administration (FDA) has approved FORTESTA Gel for the treatment of low testosterone, or 'Low T,' also known as hypogonadism. Symptoms associated with Low T include erectile dysfunction and decreased sexual desire, fatigue and loss of energy, mood depression, regression of secondary sexual characteristics and osteoporosis.

29 Dec 2010

Experimental device for obstructive sleep apnea

Obstructive sleep apnea, a dangerous sleep disorder that affects millions of Americans may have found a cure. The disease commonly manifested as snoring but leading to tremendous sleep deprivation can be severely debilitating. Sleep deprivation may lead to car crashes, accidents, high blood pressure, heart attack, stroke, and diabetes.

29 Dec 2010

Florida Hospital, Sanford-Burnham and Takeda enter obesity research collaboration

Florida Hospital, Sanford-Burnham Medical Research Institute (Sanford-Burnham), and Takeda Pharmaceutical Company Limited (Takeda)(TSE: 4502), announced today that they have signed a research agreement to form a collaboration to discover and evaluate new therapeutic approaches to obesity, a growing worldwide health problem. The partnership aligns complementary strengths in biomedical research, clinical research and drug development to identify and validate obesity- related biomarkers and new peripheral molecular targets of mutual interest.

29 Dec 2010

Cephalon receives second FDA Complete Response Letter for NUVIGIL sNDA

Cephalon, Inc. today announced that the company received a second Complete Response Letter from the U.S. Food and Drug Administration (FDA) for the supplemental new drug application (sNDA) for NUVIGIL(R) (armodafinil) Tablets [C-IV] for the treatment of patients with excessive sleepiness associated with jet lag disorder resulting from eastbound travel. In its letter to the company, the FDA reiterated its previously stated concerns regarding the NUVIGIL sNDA.

28 Dec 2010

VIVUS seeks marketing approval of QNEXA in the EU

VIVUS, Inc. today announced that the company filed a Marketing Authorization Application (MAA) with the European Medicines Agency (EMA) for QNEXA® (phentermine/topiramate) Controlled Release Capsules in the European Union (EU). The proposed indication in the EU is for the treatment of obesity, including weight loss and maintenance of weight loss, and should be used in conjunction with a mildly hypocaloric diet.

20 Dec 2010

VIVUS submits briefing document to FDA in effort to secure regulatory approval for QNEXA

VIVUS, Inc. today announced that the company, as part of its continuing effort to secure regulatory approval for QNEXA® in the U.S., submitted a briefing document to the Food and Drug Administration (FDA) designed to address items in the FDA's Complete Response Letter (CRL), issued on October 28, 2010. The company also announced that the Endocrine and Metabolic Division of the FDA has granted VIVUS a meeting in the second half of January 2011 to discuss the content of the proposed resubmission.

14 Dec 2010

Research into hospital bed technology could soon represent giant leap forward in patient care

A University of New Hampshire professor's research into hospital bed technology could soon represent a giant leap forward in patient care.

9 Dec 2010

FDA advisory committee's approval of Contrave for obesity encourages OAC, TOS, ASMBS

The Obesity Action Coalition, The Obesity Society and the American Society for Metabolic and Bariatric Surgery found encouragement in the outcome of today's advisory committee hearing, favoring approval for the first new obesity treatment in more than 10 years.

8 Dec 2010

CSC's Leading Edge Forum: Disruptive technologies to reshape delivery of healthcare

CSC's Leading Edge Forum today released a report that identifies a new wave of disruptive technologies that will reshape the delivery of healthcare. These new technologies will help control costs while improving health by ushering in an era of wellness, self-monitoring, increased and earlier detection of disease, and more effective treatments.

7 Dec 2010

VIVUS reports positive results from avanafil phase 3 study in erectile dysfunction

VIVUS, Inc. today announced positive results from TA-314, a phase 3 pivotal open-label safety study of avanafil, an investigational drug for the treatment of erectile dysfunction (ED). The study met all primary endpoints by demonstrating improvement from baseline in erectile function as measured by the Sexual Encounter Profile (both SEP2 and SEP3) and improvements in the International Index of Erectile Function (IIEF).

7 Dec 2010

FDA Advisory Committee votes in favor of expanded use of LAP-BAND gastric band

Allergan, Inc. (NYSE: AGN) today announced the U.S. Food and Drug Administration (FDA) Gastroenterology and Urology Devices Panel of the Medical Devices Advisory Committee has recommended with an 8-2 vote that the FDA extend the currently approved use of the LAP-BAND® System, Allergan's gastric band, on the basis of a favorable benefit-risk profile for weight reduction in obese adults who have failed more conservative weight reduction alternatives and have a Body Mass Index (BMI) of at least 35 or a BMI ≥30 and at least one comorbid condition.

4 Dec 2010

SLEEP ACCESS to deliver customized driver fatigue programs

Five state trucking associations have already taken decisive action on preparing their membership for a regulation on fatigued driving and the prevalence of sleep apnea in the trucking industry.

3 Dec 2010

Sleep HealthCenters enters agreement with U.S. HealthWorks to provide sleep medicine services

Sleep HealthCenters has entered into an agreement with U.S. HealthWorks to provide sleep medicine services as part of their occupational medicine programs.

2 Dec 2010

FDA approves Inspire to begin STAR clinical trial to evaluate UAS therapy for OSA

Inspire Medical Systems, a leading developer of neuro-stimulation therapies for the treatment of obstructive sleep apnea (OSA), announced today that the company has received approval from the U.S. Food and Drug Administration (FDA) to begin its STAR pivotal clinical trial. The STAR trial (Stimulation Therapy for Apnea Reduction), is a multi-center study that will evaluate both the safety and effectiveness of Inspire Upper Airway Stimulation (UAS) therapy in patients with moderate to severe obstructive sleep apnea (OSA).

30 Nov 2010

People with OSA are prone to develop atherosclerosis: Study

People with obstructive sleep apnea (OSA), a sleep disorder associated with obesity, have more non-calcified or "bad" plaque in their coronary arteries, according to a study presented today at the annual meeting of the Radiological Society of North America (RSNA).

30 Nov 2010

Sleep Apnea News and Research

Researchers examine brain's role in breathing

CareCore National and D3 partner to accelerate implementation of cancer care pathways

Polysomnography may predict adverse outcomes following pediatric adenotonsillectomy: Study

Metabolic cost of missing one night of sleep equivalent to walking two miles

New guideline provides evidence-based recommendation for children undergoing tonsillectomy

FDA approves Endo's FORTESTA Gel for low testosterone

Experimental device for obstructive sleep apnea

Florida Hospital, Sanford-Burnham and Takeda enter obesity research collaboration

Cephalon receives second FDA Complete Response Letter for NUVIGIL sNDA

VIVUS seeks marketing approval of QNEXA in the EU

VIVUS submits briefing document to FDA in effort to secure regulatory approval for QNEXA

Research into hospital bed technology could soon represent giant leap forward in patient care

FDA advisory committee's approval of Contrave for obesity encourages OAC, TOS, ASMBS

CSC's Leading Edge Forum: Disruptive technologies to reshape delivery of healthcare

VIVUS reports positive results from avanafil phase 3 study in erectile dysfunction

FDA Advisory Committee votes in favor of expanded use of LAP-BAND gastric band

SLEEP ACCESS to deliver customized driver fatigue programs

Sleep HealthCenters enters agreement with U.S. HealthWorks to provide sleep medicine services

FDA approves Inspire to begin STAR clinical trial to evaluate UAS therapy for OSA

People with OSA are prone to develop atherosclerosis: Study

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News